

## Improving biopharmaceutical properties of diacerein using crystal engineering approach

**Rajeshri D Patel, Riddhi H Shukla, Prakruti R Buch, Tejas P Sharma and Mihir K Raval**

Saurashtra University, India

Manipulating the biopharmaceutical properties of poorly water-soluble drug molecule seems to be the need of the hour in pharmaceutical industry nowadays. The phenomenon of multi-component crystalline adducts such as salts, co-crystal, eutectics, solid solutions etc., has attracted interest from majority of crystal engineering and pharmaceutical researchers in the past decade to improve the said properties of drug molecule. In context to this, the present research work was aimed to prepare co-crystal of diacerein (DIA) with improved biopharmaceutical properties. Temperature-composition phase diagrams of DIA and conformers were constructed using DSC thermograms obtained for mixtures prepared by liquid assisted grinding. Apart from characteristic V shaped binary phase diagram, no noticeable changes in the FT-IR and PXRD spectra further confirmed eutectic formation of DIA with fumaric acid-FMA (1:2) and 2, 4-dihydroxy benzoic acid-DHA (1:3). As adhesive forces established by complimentary functional groups on DIA and conformers were unable to overcome the stress due to size shape mismatch of component molecules, explains the formation of eutectics. Kinetic solubility in 0.1 N HCl (pH 1.2), acetate buffer (pH 4.5), and phosphate buffer (pH 6.8) was conducted, it revealed that eutectics showed higher solubility than their physical mixtures vis-a-vis parent drug in all three medias. *In-vitro* dissolution and bioavailability profiles of prepared eutectics were improved as compared with pure DIA. Additionally, the study demonstrated that flow properties and tableability of eutectics were enhanced as compared to DIA alone. Thus, produced eutectics of DIA-FMA and DIA-DHA systems having fast dissolving capabilities, improved tableability and enhanced in-vivo performance make them more favourable candidates for better dosage form development.